Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, St. James's University Hospital, Leeds LS9 7TF, UK.
Oncol Rep. 2013 Oct;30(4):1575-80. doi: 10.3892/or.2013.2666. Epub 2013 Aug 8.
An effective circulating tumour marker is needed for melanoma especially with the advent of targeted therapies. Gene expression studies examining primary melanomas have shown that increased expression of osteopontin (SPP1) is associated with poor prognosis. Studies subsequently reported higher blood levels in melanoma patients with metastatic disease than those without. This study was designed to determine whether osteopontin plasma concentrations in disease-free patients after initial treatment predict survival. An enzyme-linked immunosorbent assay (ELISA) was used to measure osteopontin levels in stored plasma samples (N=215) from participants in the Leeds Melanoma Cohort. AJCC stage at sampling was statistically significant associated with osteopontin levels (p=0.03). Participants with untreated stage IV disease at sampling (n=10) had higher median osteopontin levels compared to those with treated stage I-III disease (n=158) (p<0.001) confirming previous findings. There was a trend for increased risk of death with increasing osteopontin levels but this was not statistically significant. If a level of 103.14 ng/ml (95th centile of healthy controls) was taken as the upper end of the normal range then 2.5% of patients with treated stage I-III (4/110), 17.6% of patients with untreated stage III (3/17) and 30% of patients with untreated stage IV disease (3/10) had higher levels. These findings suggest that plasma osteopontin levels warrant investigation as a tumour marker in a larger study in which the significance of change in levels over time should be studied in relation to detectable disease recurrence.
对于黑色素瘤来说，尤其在出现靶向治疗的情况下，需要一种有效的循环肿瘤标志物。研究原发性黑色素瘤的基因表达显示，骨桥蛋白（SPP1）表达增加与预后不良有关。随后的研究报告称，转移性黑色素瘤患者的血液中骨桥蛋白水平高于无转移性疾病的患者。本研究旨在确定初始治疗后无疾病患者的血浆骨桥蛋白浓度是否可以预测生存。使用酶联免疫吸附试验（ELISA）测量了莱斯特黑色素瘤队列参与者储存的血浆样本（N=215）中的骨桥蛋白水平。采样时的 AJCC 分期与骨桥蛋白水平呈统计学显著相关（p=0.03）。与接受治疗的 I-III 期疾病患者（n=158）相比，未接受治疗的 IV 期疾病患者（n=10）在采样时的中位骨桥蛋白水平更高（p<0.001），证实了先前的发现。骨桥蛋白水平升高与死亡风险增加呈趋势，但无统计学意义。如果将 103.14ng/ml（健康对照组 95%的百分位数）作为正常范围的上限，那么在接受治疗的 I-III 期患者中，有 2.5%（4/110）、未接受治疗的 III 期患者中，有 17.6%（3/17）和未接受治疗的 IV 期患者中，有 30%（3/10）的患者骨桥蛋白水平更高。这些发现表明，血浆骨桥蛋白水平值得在更大的研究中进一步研究，其中应研究水平随时间的变化与可检测到的疾病复发之间的关系。
